NEW YORK, Nov. 4 (GenomeWeb News) - Becton Dickinson today reported that total revenues increased 8 percent in the third quarter to $1.3 billion from $1.2 billion year over year.
Sales at BD's Biosciences unit were flat at $89 million.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.